Fast growing in oncology - Director AstraZeneca Employee Review

4.0
Mar 10, 2024
Recommend
CEO approval
Business Outlook

Pros

Innovative pipelines both in-house and in-license, a lot of learning opportunities.

Cons

Overwhelming workload in oncology, talent retention/new hires can't keep the exponential growth of portfolio in oncology.

Explore other reviews about AstraZeneca

5.0
Jun 25, 2026
Recommend
CEO approval
Business Outlook

Pros

Good products, great oncology pipeline

Cons

Global leaders moving to US that have limited understanding of US environment

4.0
Jun 29, 2026
Recommend
CEO approval
Business Outlook

Pros

Lots to learn with multiple launches and focus on AI

Cons

heavy middle layer slows down decision making

See reviews by: Helpful|Rating|Date|All